MicroRNAs and Cytokines in Peri-Implantitis Tissue

NCT ID: NCT05765942

Last Updated: 2023-03-17

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 45 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-06-01
• Study Completion Date: 2023-12-01

Brief Summary

Peri-implantitis is a non-linear and accelerating pattern of loss of supporting bone tissue associated with clinical signs of inflammation and increased probing depths compared to baseline measurements. It can present as an asymptomatic condition with infection and fast progression of bone resorption or clinically symptomatic with mucosal inflammation, redness, edema, mucosal enlargement, bleeding on probing (BOP), suppuration, increased probing depth, and radiographic bone loss. The host immune defense against bacterial challenge is responsible for the damage, and the local immune-inflammatory process is associated with disrupted bone remodeling. New studies looking for predictive and accurate early biomarkers for this pathology have the utmost relevance. David Baltimore et al. proposed a feedback loop involving miRNA-146a and TLR signaling, which has been shown to be up-regulated in inflammatory diseases such as osteoarthritis and rheumatoid arthritis.

miRNA-146a and miRNA-155 were the first miRNAs identified to be induced in immune cells stimulated by TLRs and proinflammatory cytokines. Precision medicine uses molecular research and different biomarkers, population studies, and big data analysis to recreate complex disease models. Several studies have compared the miRNA profiles of patients with periodontitis with healthy patients. Although periodontitis and peri-implantitis share many features, researchers' findings of periodontitis are not necessarily applicable to peri-implantitis. In fact, based on emerging evidence, peri-implantitis, and periodontitis exhibit several key differences, including their histopathological and molecular characteristics. Considering the aforementioned analysis, inflammatory miRNAs may be differentially expressed in peri-implantitis tissue compared with healthy gingival tissue. This study will investigate the gene expression levels of miRNA-146a and miRNA-155 and their correlation with inflammatory levels of their target genes in human gingival tissue surrounding dental implants diagnosed with peri-implantitis and health.

Detailed Description

MiRNAs are small non-coding RNA molecules that are approximately 18-22 non-transcribed spacer NTS long. These single-stranded molecules regulate gene expression by binding to the complementary sequences in the 3-untranslated or coding region of the target mRNAs, leading to either blockade of translation or induction of target mRNA degradation. Therefore, miRNAs participate in not only physiological processes within cells and tissues but also pathological processes. According to previous reports, miRNAs are specifically involved in many inflammatory and bone-related diseases, such as rheumatoid arthritis, osteoporosis, and periodontitis.

The miRNA-146 family is composed of two members, miRNA-146a and miRNA-146b that are located on chromosomes 5 and 10, respectively. proposed a feedback loop involving miRNA-146a and TLR signaling. They found the induction of transcription of miRNA-146a by lipopolysaccharide LPS, tumor necrosis factor-alpha (TNFa) and interleukin-1b (IL-1b) is dependent on NF-kb, and that in turn, miRNA-146a potentially targets tumor necrosis factor receptor-associated family (TRAF6) and interleukin-1 receptor-associated kinase (IRAK1), implicating it as a negative regulator fine-tuning the immune response. As stated, too strong or too prolonged induction of the innate immune response can have detrimental effects resulting in acute and chronic inflammatory disorders. The high expression of miRNA-146a is up-regulated in many inflammatory diseases such as osteoarthritis and rheumatoid arthritis (RA), the latter involving up-regulation following stimulation with inflammatory cytokines such as TNF-a and IL1-b. Interestingly, a polymorphism in the 3-untranslated region (3-UTR) of the mRNA encoding the miR-146a target IRAK1 is associated with susceptibility to Rheumatoid Arthritis and psoriatic arthritis.

MiRNA-146a and miRNA-155 were the first miRNAs identified to be induced in immune cells stimulated by TLRs and proinflammatory cytokines. In human and murine immune cells, miRNA-155 can be classified as an early response gene, since its expression is highly induced within 2 h of TLR activation (TLR2, TLR3, TLR4, and TLR9). MiRNA-155 negatively regulates TLR-signaling by targeting key signaling molecules, including TAB2, MyD88, and NF-kb subunit p65. Overexpression of miRNA-155 suppresses the production of the proinflammatory cytokines IL-8 and TNF-a, whereas IL-10, which exerts anti-inflammatory properties, inhibits miR-155 expression to maintain homeostasis. MiR-155 also facilitates CXCL12 signaling through the inhibition of SHIP-1, a negative regulator of TLR-induced signals. Moreover, SHIP-1 regulation by miR-155 controls the pathogenesis of experimental colitis, suggesting that miR-155 can also have proinflammatory functions.

The advances made in proteomics, genomics, and molecular biology aid in the control and treatment of the disease by taking advantage of precision or stratified medicine, i.e. "segregating the individuals into subpopulations who vary in their disease susceptibility and response to a precise treatment". Precision medicine uses molecular research and different biomarkers, population studies, and big data analysis to recreate complex disease models. It seems reasonable to expect that in the future, the accuracy, predictive values, and advantages of these predictive models which include new molecular candidates could benefit and improve the control of different multifactorial and complex diseases, such as peri-implantitis. Indeed, this approach has been considerably developed in oncology and genetic diseases, but it is still under progress in the dental field. Expanding the research of new molecules and biomarkers in peri-implant tissues would allow us to monitor the clinical status of the implants, to classify them as well as the patients according to their real risk of developing biological complications. In this regard, an important class of gene modulators that have been scarcely explored in the context of periimplantitis include miRNAs.

Several studies have compared the miRNA profiles of patients with periodontitis with healthy patients. Although periodontitis and peri-implantitis share many features, researchers' findings of periodontitis are not necessarily applicable to peri-implantitis. Based on emerging evidence, peri-implantitis, and periodontitis exhibit several key differences, including their histopathological and molecular characteristics. Considering the aforementioned analysis, inflammatory miRNAs may be differentially expressed in peri-implantitis tissue compared with healthy gingival tissue.

Conditions

Peri-implantitis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Implant surgery for harvesting healthy implant tissue (group HP)

the preoperative mucosal thickness will be measured clinically using a periodontal probe. A crestal incision will be performed, and a full-thickness flap will be elevated. Following the osteotomy, one or more implants measuring 4.5 or 5.0 mm in diameter will be placed. The implant platform will be positioned 0.5 mm below the bone level. A narrow-diameter healing abutment designed specifically for this study will be screwed in at 20 N, and flaps will be repositioned and sutured to obtain optimal adaptation of the mucosa to the titanium abutment. Healthy tissue samples will be harvested after 2 months of healing. Before the surgery, a guide pin will be connected to each healing abutment, attached to a circular punch 5 mm wide and with a cutting edge, which screwed apically around the abutment. Hence, a 1.5 mm thick collar of peri-implant soft tissue will be harvested Then, a new 4.5-5.0 mm-wide smooth-surfaced healing abutment will be connected to the implant directly.

No interventions assigned to this group

Implant surgery for harvesting peri-implantitis tissue (group PP)

In each patient, at least one implant site demonstrating signs of peri-implantitis will be selected for biopsy. The site will be anesthetized and two parallel incisions, about 3mm apart, will be made with a 15C scalpel blade through the soft tissue until bone contact would be achieved. The 2 incisions will be connected with a perpendicular incision that will be placed at a distance of 4 mm from the proximal surface of the implant. The biopsies, including the entire supra-crestal soft tissue portion of the diseased site, will be carefully retrieved

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Peri-implant health (control group):

• Adult patient age between >18years.
• Having one or more missing teeth will be replaced with dental implants.
• Having adequate bone quality and availably for implant placement of 4.5-5 mm diameter and 8.5-13 mm length.
• Having keratinized mucosa of at least 3mm.
• Having no systemic disorders contraindicating to have peri-implant therapy.

2. Peri-implantitis (test group):

• Adult patient age between >18 years old.
• Having at least one implant with > 1 year in function.
• Presence of bleeding and/or suppuration on gentle probing.
• Increased probing pocket depth (PPD) compared with previous baseline data
• Presence of bone loss beyond initial bone remodeling levels.

In the absence of previous examination data diagnosis of peri-implantitis can be based on the combination of:

• Presence of bleeding and/or suppuration on gentle probing.
• PPD of ≥6 mm.
• Bone levels ≥3 mm apical of the most coronal portion of the intraosseous part of the implant.

Exclusion Criteria

• Chronic inflammatory diseases such as : type 1 or 2 diabetes, cardiovascular or autoimmune diseases, and active infectious diseases.
• Systemic or topical antimicrobial/anti-inflammatory therapy for the 3 months prior to the beginning of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Baghdad

OTHER

Sponsor Role: lead

Responsible Party

munir nasr

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Munir

Baghdad, , Iraq

Countries

Iraq

Other Identifiers

534622

Identifier Type: -

Identifier Source: org_study_id